Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:daclatasvir
|
| gptkbp:activities |
N S5 A inhibitor
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:can_be_used_with |
gptkb:sofosbuvir
|
| gptkbp:clinical_trial |
Phase III
approximately 67% |
| gptkbp:contraindication |
severe liver disease
|
| gptkbp:developed_by |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:dosage_form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Daklinza
|
| gptkbp:ingredients |
gptkb:daclatasvir
C23 H25 Cl N6 O3 S |
| gptkbp:invention |
2029
|
| gptkbp:is_atype_of |
J05 A P05
|
| gptkbp:is_used_for |
treatment of hepatitis C
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States |
| gptkbp:name |
Essential Medicines
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea insomnia |
| gptkbp:traded_on |
gptkb:Daklinza
|